NASDAQ:VVOS Vivos Therapeutics (VVOS) Stock Price, News & Analysis → The Worst is Yet to Come… (From Porter & Company) (Ad) Free VVOS Stock Alerts $2.02 -0.07 (-3.35%) (As of 06/3/2024 ET) Add Compare Share Share Today's Range$2.00▼$2.1150-Day Range$1.93▼$4.8352-Week Range$1.91▼$48.79Volume17,922 shsAverage Volume156,563 shsMarket Capitalization$6.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Vivos Therapeutics alerts: Email Address Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. About Vivos Therapeutics Stock (NASDAQ:VVOS)Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.Read More VVOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VVOS Stock News HeadlinesJune 1 at 7:28 AM | americanbankingnews.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Down 26.1% in MayMay 19, 2024 | msn.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2024 Earnings Call TranscriptMay 15, 2024 | msn.comVivos Therapeutics GAAP EPS of -$1.63, revenue of $3.4MMay 15, 2024 | finance.yahoo.comVivos Therapeutics Inc (VVOS) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 14, 2024 | investorplace.comVVOS Stock Earnings: Vivos Therapeutics Reported Results for Q1 2024May 14, 2024 | proactiveinvestors.comVivos Therapeutics reports first quarter cost savings, launches revenue-generating initiativeMay 14, 2024 | globenewswire.comVivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational UpdateMay 14, 2024 | globenewswire.comVivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference CallApril 11, 2024 | proactiveinvestors.comVivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approvalApril 9, 2024 | finance.yahoo.comVivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical DevicesApril 9, 2024 | markets.businessinsider.comVivos Gets Approval To Facilitate Full Medicare Reimbursement For CARE Sleep Apnea Oral DevicesApril 9, 2024 | msn.comWhat's Going On With Vivos Therapeutics Stock?April 9, 2024 | msn.comMedicare to reimburse for Vivos CARE sleep apnea devicesApril 9, 2024 | proactiveinvestors.comVivos Therapeutics CARE oral medical devices approved for Medicare reimbursementApril 9, 2024 | investorplace.comWhy Is Vivos Therapeutics (VVOS) Stock Up 16% Today?April 9, 2024 | msn.comVivos Therapeutics files to sell 1.73M shares of common stock for holdersApril 9, 2024 | finance.yahoo.comVivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementApril 9, 2024 | globenewswire.comVivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementApril 1, 2024 | proactiveinvestors.comVivos Therapeutics highlights path to cash flow positivity after FDA clearanceMarch 31, 2024 | finance.yahoo.comVivos Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 30, 2024 | seekingalpha.comVivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | marketwatch.comVivos Therapeutics Shares Fall After Wider-Than-Expected 4Q LossMarch 28, 2024 | globenewswire.comVivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational UpdateMarch 28, 2024 | globenewswire.comVivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference CallFebruary 22, 2024 | benzinga.comVivos Therapeutics Stock (NASDAQ:VVOS), Short Interest ReportSee More Headlines Receive VVOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today6/03/2024Next Earnings (Estimated)8/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:VVOS CUSIPN/A CIK1716166 Webwww.vivoslife.com Phone866-908-4867FaxN/AEmployees114Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($10.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,580,000.00 Net Margins-117.06% Pretax Margin-117.06% Return on Equity-1,879.30% Return on Assets-126.83% Debt Debt-to-Equity RatioN/A Current Ratio0.45 Quick Ratio0.45 Sales & Book Value Annual Sales$13.80 million Price / Sales0.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book9.25Miscellaneous Outstanding Shares3,230,000Free Float2,917,000Market Cap$6.57 million OptionableNo Data Beta7.81 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. R. Kirk Huntsman (Age 66)Co-Founder, Chairman of the Board & CEO Comp: $482.16kMr. Bradford K. Amman (Age 62)CFO, Treasurer & Secretary Comp: $335.53kMr. Todd HuntsmanCo-Founder & Senior VP of Product and TechnologyMs. RaeAnn ByrnesCo-Founder and Senior VP of Events & Clinical Advisory ServicesMs. Susan McCulloughCo-Founder & Executive VP of OperationsMs. Julie GannonSenior VP of Strategic Sales & Marketing and Investor Relations OfficerMr. Nicholas M. DeGennaroSenior Vice President of Medical Integration DivisionMs. Ruth HembreeSenior Vice President of Practice ServicesMs. Stephanie HuebnerSenior Vice President of Dental Service IntegrationMr. John BallardSenior Vice President of TechnologyMore ExecutivesKey CompetitorsInspira Technologies Oxy B.H.N.NASDAQ:IINNNephrosNASDAQ:NEPHLyra TherapeuticsNASDAQ:LYRAMeihua International Medical TechnologiesNASDAQ:MHUAPAVmedNASDAQ:PAVMView All CompetitorsInsidersRonald Kirk HuntsmanBought 560 shares on 6/20/2023Total: $7,420.00 ($13.25/share)Ronald Kirk HuntsmanBought 600 shares on 6/16/2023Total: $8,100.00 ($13.50/share)Ronald Kirk HuntsmanBought 400 shares on 6/14/2023Total: $4,900.00 ($12.25/share)View All Insider Transactions VVOS Stock Analysis - Frequently Asked Questions How have VVOS shares performed in 2024? Vivos Therapeutics' stock was trading at $12.44 on January 1st, 2024. Since then, VVOS shares have decreased by 83.8% and is now trading at $2.02. View the best growth stocks for 2024 here. Are investors shorting Vivos Therapeutics? Vivos Therapeutics saw a drop in short interest in May. As of May 15th, there was short interest totaling 46,400 shares, a drop of 26.1% from the April 30th total of 62,800 shares. Based on an average daily volume of 170,200 shares, the short-interest ratio is currently 0.3 days. Approximately 1.6% of the company's stock are short sold. View Vivos Therapeutics' Short Interest. When is Vivos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 21st 2024. View our VVOS earnings forecast. How were Vivos Therapeutics' earnings last quarter? Vivos Therapeutics, Inc. (NASDAQ:VVOS) announced its quarterly earnings results on Thursday, March, 28th. The company reported ($3.05) earnings per share for the quarter. The business had revenue of $3.25 million for the quarter. Vivos Therapeutics had a negative net margin of 117.06% and a negative trailing twelve-month return on equity of 1,879.30%. When did Vivos Therapeutics' stock split? Shares of Vivos Therapeutics reverse split on Friday, October 27th 2023. The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Vivos Therapeutics IPO? Vivos Therapeutics (VVOS) raised $20 million in an IPO on Friday, December 11th 2020. The company issued 3,300,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners served as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers. How do I buy shares of Vivos Therapeutics? Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VVOS) was last updated on 6/4/2024 by MarketBeat.com Staff From Our PartnersNvidia’s Quiet $1 Trillion PivotWeiss RatingsThe Only Energy Play You Should Be Looking AtWealthpin ProClaim Your Complimentary Bitcoin RewardCrypto Swap Profits[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaElon Musk’s Final Masterpiece: “X-9840”Paradigm PressPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyBUY ALERT: Tiny tech play partners with US governmentStansberry ResearchCollapse of the Petrodollar Colonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
